1-Bromoadamantane

sc-237494

Material Safety Data Sheet



Hazard Alert Code Key:

EXTREME

HIGH

MODERATE

LOW

Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

PRODUCT NAME

1-Bromoadamantane

STATEMENT OF HAZARDOUS NATURE

CONSIDERED A HAZARDOUS SUBSTANCE ACCORDING TO OSHA 29 CFR 1910.1200.

NFPA



SUPPLIER

Santa Cruz Biotechnology, Inc. 2145 Delaware Avenue Santa Cruz, California 95060 800.457.3801 or 831.457.3800

EMERGENCY

ChemWatch

Within the US & Canada: 877-715-9305 Outside the US & Canada: +800 2436 2255 (1-800-CHEMCALL) or call +613 9573 3112

C10-H15-Br, "adamantane, 1-bromo-", "1-adamantyl bromide"

Section 2 - HAZARDS IDENTIFICATION

CHEMWATCH HAZARD RATINGS

Max Flammability: 1 Toxicity: 2 Min/Nil=0 **Body Contact:** 0 Low=1 Moderate=2 Reactivity: High=3 Chronic: 3 Extreme=4





CANADIAN WHMIS SYMBOLS





EMERGENCY OVERVIEW

RISK

Harmful if swallowed.

Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

POTENTIAL HEALTH EFFECTS

ACUTE HEALTH EFFECTS

SWALLOWED

■ Accidental ingestion of the material may be harmful; animal experiments indicate that ingestion of less than 150 gram may be fatal or may produce serious damage to the health of the individual.

FYF

■ Although the material is not thought to be an irritant, direct contact with the eye may cause transient discomfort characterized by tearing or conjunctival redness (as with windburn).

Slight abrasive damage may also result.

SKIN

■ Skin contact is not thought to produce harmful health effects (as classified using animal models).

Systemic harm, however, has been identified following exposure of animals by at least one other route and the material may still produce health damage following entry through wounds, lesions or abrasions.

- Open cuts, abraded or irritated skin should not be exposed to this material.
- Entry into the blood-stream, through, for example, cuts, abrasions or lesions, may produce systemic injury with harmful effects.

Examine the skin prior to the use of the material and ensure that any external damage is suitably protected.

INHALED

■ The material is not thought to produce either adverse health effects or irritation of the respiratory tract following inhalation (as classified using animal models).

Nevertheless, adverse effects have been produced following exposure of animals by at least one other route and good hygiene practice requires that exposure be kept to a minimum and that suitable control measures be used in an occupational setting.

■ Persons with impaired respiratory function, airway diseases and conditions such as emphysema or chronic bronchitis, may incur further disability if excessive concentrations of particulate are inhaled.

CHRONIC HEALTH EFFECTS

■ Limited evidence suggests that repeated or long-term occupational exposure may produce cumulative health effects involving organs or biochemical systems.

There is some evidence that human exposure to the material may result in developmental toxicity. This evidence is based on animal studies where effects have been observed in the absence of marked maternal toxicity, or at around the same dose levels as other toxic effects but which are not secondary non-specific consequences of the other toxic effects.

Long term exposure to high dust concentrations may cause changes in lung function i.e. pneumoconiosis; caused by particles less than 0.5 micron penetrating and remaining in the lung.

Chronic intoxication with ionic bromides, historically, has resulted from medical use of bromides but not from environmental or occupational exposure; depression, hallucinosis, and schizophreniform psychosis can be seen in the absence of other signs of intoxication. Bromides may also induce sedation, irritability, agitation, delirium, memory loss, confusion, disorientation, forgetfulness (aphasias), dysarthria, weakness, fatigue, vertigo, stupor, coma, decreased appetite, nausea and vomiting, diarrhoea, hallucinations, an acne like rash on the face, legs and trunk, known as bronchoderma (seen in 25-30% of case involving bromide ion), and a profuse discharge from the nostrils (coryza). Ataxia and generalised hyperreflexia have also been observed. Correlation of neurologic symptoms with blood levels of bromide is inexact. The use of substances such as brompheniramine, as antihistamines, largely reflect current day usage of bromides; ionic bromides have been largely withdrawn from therapeutic use due to their toxicity. Several cases of foetal abnormalities have been described in mothers who took large doses of bromides during pregnancy.

| Section 3 - COMPOSITION / INFORMATION ON INGREDIENTS | | | | | | |
|--|----------|-----|--|--|--|--|
| NAME | CAS RN | % | | | | |
| 1-bromoadamantane | 768-90-1 | >98 | | | | |

Section 4 - FIRST AID MEASURES

SWALLOWED

· IF SWALLOWED, REFER FOR MEDICAL ATTENTION, WHERE POSSIBLE, WITHOUT DELAY. · Where Medical attention is not immediately available or where the patient is more than 15 minutes from a hospital or unless instructed otherwise:

FYF

■ If this product comes in contact with the eyes: Wash out immediately with fresh running water. Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids.

SKIN

■ If skin or hair contact occurs: · Flush skin and hair with running water (and soap if available). · Seek medical attention in event of irritation.

INHALED

· If dust is inhaled, remove from contaminated area. · Encourage patient to blow nose to ensure clear passage of breathing. · If irritation or discomfort persists seek medical attention.

NOTES TO PHYSICIAN

 \blacksquare for poisons (where specific treatment regime is absent):

------BASIC TREATMENT

......

- · Establish a patent airway with suction where necessary.
- · Watch for signs of respiratory insufficiency and assist ventilation as necessary.

Treat symptomatically.

| Section 5 - FIRE FIGHTING MEASURES | | | | | |
|------------------------------------|----------------|--|--|--|--|
| Vapour Pressure (mmHG): | Negligible | | | | |
| Upper Explosive Limit (%): | Not available. | | | | |
| Specific Gravity (water=1): | Not available | | | | |
| Lower Explosive Limit (%): | Not available | | | | |

EXTINGUISHING MEDIA

- · Foam.
- · Dry chemical powder.

FIRE FIGHTING

- · Alert Emergency Responders and tell them location and nature of hazard.
- · Wear breathing apparatus plus protective gloves.

When any large container (including road and rail tankers) is involved in a fire,

consider evacuation by 100 metres in all directions.

GENERAL FIRE HAZARDS/HAZARDOUS COMBUSTIBLE PRODUCTS

- · Combustible solid which burns but propagates flame with difficulty.
- · Avoid generating dust, particularly clouds of dust in a confined or unventilated space as dusts may form an explosive mixture with air, and any source of ignition, i.e. flame or spark, will cause fire or explosion. Dust clouds generated by the fine grinding of the solid are a particular hazard; accumulations of fine dust may burn rapidly and fiercely if ignited.

Combustion products include: carbon monoxide (CO), carbon dioxide (CO2), hydrogen bromide, other pyrolysis products typical of burning organic material.

FIRE INCOMPATIBILITY

■ Avoid contamination with oxidizing agents i.e. nitrates, oxidizing acids,chlorine bleaches, pool chlorine etc. as ignition may result.

PERSONAL PROTECTION

Glasses:

Chemical goggles.

Gloves:

Respirator:

Particulate

Section 6 - ACCIDENTAL RELEASE MEASURES

MINOR SPILLS

- · Remove all ignition sources.
- · Clean up all spills immediately.
- \cdot Avoid contact with skin and eyes.
- \cdot Control personal contact by using protective equipment.
- · Use dry clean up procedures and avoid generating dust.
- · Place in a suitable, labelled container for waste disposal.

Environmental hazard - contain spillage.

MAJOR SPILLS

■ Environmental hazard - contain spillage.

Moderate hazard.

- · CAUTION: Advise personnel in area.
- · Alert Emergency Responders and tell them location and nature of hazard.

Section 7 - HANDLING AND STORAGE

PROCEDURE FOR HANDLING

- · Avoid all personal contact, including inhalation.
- · Wear protective clothing when risk of exposure occurs.

Empty containers may contain residual dust which has the potential to accumulate following settling. Such dusts may explode in the presence of an appropriate ignition source.

- · Do NOT cut, drill, grind or weld such containers.
- · In addition ensure such activity is not performed near full, partially empty or empty containers without appropriate workplace safety authorisation or permit.

RECOMMENDED STORAGE METHODS

- · Polyethylene or polypropylene container.
- · Check all containers are clearly labelled and free from leaks.

STORAGE REQUIREMENTS

■ Observe manufacturer's storing and handling recommendations.

Section 8 - EXPOSURE CONTROLS / PERSONAL PROTECTION

EXPOSURE CONTROLS

| Source | Material | TWA ppm | TWA mg/m³ | STEL ppm | STEL mg/m³ | Peak ppm | Peak mg/m³ | TWA F/CC | Notes |
|--|---|---------|--------------|-------------|---------------|----------|---------------|-------------|---|
| Canada - British Columbia Occupational Exposure Limits | 1-bromoadamantane (Particles (Insoluble or Poorly Soluble) Not Otherwise Classified (PNOC)) | | 10 (N) | | | | | | |
| US - Wyoming Toxic and Hazardous Substances Table Z1 Limits for Air Contaminants | 1-bromoadamantane (Particulates not otherwise regulated (PNOR)(f)- Respirable fraction) | | 5 | | | | | | |
| US - Tennessee Occupational Exposure Limits - Limits For Air Contaminants | 1-bromoadamantane (Particulates not otherwise regulated Respirable fraction) | | 5 | | | | | | |
| US - California Permissible Exposure Limits for Chemical Contaminants | 1-bromoadamantane (Particulates not otherwise regulated Respirable fraction) | | 5 | | | | | | (n) |
| US - Oregon Permissible Exposure Limits (Z-1) | 1-bromoadamantane (Particulates not otherwise regulated (PNOR) (f) Total Dust) | | 10 | | | | | | Bold print identifies substances for which the Oregon Permissible Exposure Limits (PELs) are different than the federal Limits. PNOR means "particles not otherwise regulated." |
| US - Michigan Exposure Limits for Air Contaminants | 1-bromoadamantane (Particulates not otherwise regulated, Respirable dust) | | 5 | | | | | | |
| Edward Island Occupational | 1-bromoadamantane (Particles (Insoluble or Poorly Soluble) [NOS] Inhalable particles) | | 10 | | | | | | See Appendix B current TLV/BEI Book |
| US - Oregon Permissible Exposure Limits (Z-1) | 1-bromoadamantane (Particulates not otherwise regulated (PNOR) (f) Respirable Fraction) | - | 5 | | | | | | Bold print identifies substances for which the Oregon Permissible Exposure Limits (PELs) are different than the federal Limits. PNOR means "particles not |

ENDOELTABLE

PERSONAL PROTECTION



RESPIRATOR

Particulate

Consult your EHS staff for recommendations

FYF

- · Safety glasses with side shields
- · Chemical goggles.

HANDS/FEET

- Suitability and durability of glove type is dependent on usage. Important factors in the selection of gloves include: such as:
- · frequency and duration of contact,
- · chemical resistance of glove material,
- · glove thickness and
- · dexterity

Select gloves tested to a relevant standard (e.g. Europe EN 374, US F739).

- · When prolonged or frequently repeated contact may occur, a glove with a protection class of 5 or higher (breakthrough time greater than 240 minutes according to EN 374) is recommended.
- · When only brief contact is expected, a glove with a protection class of 3 or higher (breakthrough time greater than 60 minutes according to EN 374) is recommended.
- · Contaminated gloves should be replaced.

Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturiser is recommended.

Experience indicates that the following polymers are suitable as glove materials for protection against undissolved, dry solids, where abrasive particles are not present.

- · polychloroprene
- nitrile rubber
- · butyl rubber
- · fluorocaoutchouc
- · polyvinyl chloride

Gloves should be examined for wear and/ or degradation constantly.

OTHER

- · Overalls.
- · P.V.C. apron.
- · Barrier cream.
- · Skin cleansing cream.
- · Eye wash unit.

ENGINEERING CONTROLS

- · Local exhaust ventilation is required where solids are handled as powders or crystals; even when particulates are relatively large, a certain proportion will be powdered by mutual friction.
- · Exhaust ventilation should be designed to prevent accumulation and recirculation of particulates in the workplace.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

PHYSICAL PROPERTIES

Solid.

Does not mix with water.

| State | Divided solid | Molecular Weight | 215.14 |
|---------------------------|----------------|--------------------------------|----------------|
| Melting Range (°F) | 241- 244 | Viscosity | Not Applicable |
| Boiling Range (°F) | Not available | Solubility in water (g/L) | Immiscible |
| Flash Point (°F) | Not available | pH (1% solution) | Not applicable |
| Decomposition Temp (°F) | Not available. | pH (as supplied) | Not applicable |
| Autoignition Temp (°F) | Not available | Vapour Pressure (mmHG) | Negligible |
| Upper Explosive Limit (%) | Not available. | Specific Gravity (water=1) | Not available |
| Lower Explosive Limit (%) | Not available | Relative Vapor Density (air=1) | >1 |

Volatile Component (%vol) Negligible Evaporation Rate Not applicable

APPEARANCE

White to off-white crystalline powder: does not mix well with water. Moisture sensitive.

Section 10 - CHEMICAL STABILITY

CONDITIONS CONTRIBUTING TO INSTABILITY

- · Presence of incompatible materials.
- · Product is considered stable.

STORAGE INCOMPATIBILITY

■ Avoid reaction with oxidizing agents.

For incompatible materials - refer to Section 7 - Handling and Storage.

Section 11 - TOXICOLOGICAL INFORMATION

1-bromoadamantane

TOXICITY AND IRRITATION

1-BROMOADAMANTANE:

- unless otherwise specified data extracted from RTECS Register of Toxic Effects of Chemical Substances.
- Amantadine (an adamantane or amantane) has been associated with several central nervous system side effects, likely due to amantadine's dopaminergic and adrenergic activity, and to a lesser extent, its activity as an anticholinergic.

Common side-effects associated with amantadine therapy include ankle oedema, nervous excitement, confusion, difficulty in concentration, dizziness, light-headedness, orthostatic hypotension, urinary retention, slurred speech, ataxia, depression, insomnia, lethargy, nausea, anorexia, vomiting, dry mouth, constipation, skin rash, discoloured spots or skin patches (livedo reticularis) and visual disturbances. More serious side-effects may include congestive heart-failure, psychosis and leucopenia. Dose-related responses include hallucination, feelings of detachment and convulsions.

Deaths have been reported from overdose with amantadine. The lowest reported acute lethal dose was 1 gram. Acute toxicity may be attributable to the anticholinergic effects of amantadine. Drug overdose has resulted in cardiac, respiratory, renal or central nervous system toxicity. Cardiac dysfunction includes arrhythmia, tachycardia and hypertension

Suicide attempts, some of which have been fatal, have been reported in patients treated with amantadine many of whom received short courses for influenza treatment or prophylaxis. The incidence of suicide attempts is not known and the pathophysiologic mechanism is not understood. Suicide attempts and suicidal ideation have been reported in patients with and without prior history of psychiatric illness.

Sporadic cases of possible Neuroleptic Malignant Syndrome (NMS) have been reported in association with dose reduction or withdrawal of the drug. NMS is an uncommon but life-threatening syndrome characterised by fever or hyperthermia; neurologic findings including muscle rigidity, involuntary movements, altered consciousness; mental status changes; other disturbances such as autonomic dysfunction, tachycardia, tachypnea, hyper- or hypotension; laboratory findings such as creatine phosphokinase elevation, leukocytosis, myoglobinuria, and increased serum myoglobin.

Carcinogenicity and mutagenicity: Long-term in vivo animal studies designed to evaluate the carcinogenic potential of amantadine have not been performed. In several in vitro assays for gene mutation, the drug did not increase the number of spontaneously observed mutations in four strains of Salmonella typhimurium (Ames Test) or in a mammalian cell line (Chinese Hamster Ovary cells) when incubations were performed either with or without a liver metabolic activation extract. Further, there was no evidence of chromosome damage observed in an in vitro test using freshly derived and stimulated human peripheral blood lymphocytes (with and without metabolic activation) or in an in vivo mouse bone marrow micronucleus test (140-550 mg/kg; estimated human equivalent doses of 11.7-45.8 mg/kg based on body surface area conversion).

Reproductive toxicity: In a three litter, non-GLP, reproduction study in rats, amantadine at a dose of 32 mg/kg/day (equal to the maximum recommended human dose on a mg/m2 basis) administered to both males and females slightly impaired fertility. There were no effects on fertility at a dose level of 10 mg/kg/day (or 0.3 times the maximum recommended human dose on a mg/m2 basis); intermediate doses were not tested

Failed fertility has been reported during human in vitro fertilization (IVF) when the sperm donor ingested amantadine 2 weeks prior to, and during the IVF cycle.

Developmental toxicity: The hydrochloride is embryotoxic and teratogenic in rats at 50 mg/kg/day (about 12 times a recommended human dose). These effects do not occur at 37 mg/kg/day nor do they occur in rabbits.

In two non-GLP studies in rats in which females were dosed from 5 days prior to mating to Day 6 of gestation or on Days 7-14 of gestation, amantadine produced increases in embryonic death at an oral dose of 100 mg/kg (or 3 times the maximum recommended human dose on a mg/m2 basis). In the non-GLP rat study in which females were dosed on Days 7-14 of gestation, there was a marked increase in severe visceral and skeletal malformations at oral doses of 50 and 100 mg/kg (or 1.5 and 3 times, respectively, the maximum recommended human dose on a mg/m2 basis). The no-effect dose for teratogenicity was 37 mg/kg (equal to the maximum recommended human dose on a mg/m2 basis).

Cardiovascular maldevelopment (single ventricle with pulmonary atresia) has been associated with maternal exposure to amantadine (100 mg/d) administered during the first 2 weeks of pregnancy.

No significant acute toxicological data identified in literature search.

CARCINOGEN

BROMINE COMPOUNDS (ORGANIC OR INORGANIC)

US Environmental Defense Scorecard Suspected Carcinogens

Reference(s)

P65-MC

Section 12 - ECOLOGICAL INFORMATION

Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

This material and its container must be disposed of as hazardous waste.

Avoid release to the environment.

Refer to special instructions/ safety data sheets.

Ecotoxicity

Ingredient Persistence: Water/SoilPersistence: Air Bioaccumulation Mobility
1-bromoadamantane HIGH LOW MED

Section 13 - DISPOSAL CONSIDERATIONS

Disposal Instructions

All waste must be handled in accordance with local, state and federal regulations.

| Puncture containers to prevent re-use and bury at an authorized landfill.

Legislation addressing waste disposal requirements may differ by country, state and/ or territory. Each user must refer to laws operating in their area. In some areas, certain wastes must be tracked.

A Hierarchy of Controls seems to be common - the user should investigate:

- Reduction
- · Reuse
- · Recycling
- · Disposal (if all else fails)

This material may be recycled if unused, or if it has not been contaminated so as to make it unsuitable for its intended use. Shelf life considerations should also be applied in making decisions of this type. Note that properties of a material may change in use, and recycling or reuse may not always be appropriate.

DO NOT allow wash water from cleaning equipment to enter drains. Collect all wash water for treatment before disposal.

- · Recycle wherever possible.
- · Consult manufacturer for recycling options or consult Waste Management Authority for disposal if no suitable treatment or disposal facility can be identified.

Section 14 - TRANSPORTATION INFORMATION



DOT:

Symbols: G Hazard class or Division: 9 Identification Numbers: UN3077 PG: III Label Codes: 9 Special provisions: 8, 146,

335, B54, IB8, IP3, N20, T1, TP33

Packaging: Exceptions: 155 Packaging: Non- bulk: 213 Packaging: Exceptions: 155 Quantity limitations: No limit

Passenger aircraft/rail:

Quantity Limitations: Cargo No limit Vessel stowage: Location: A

aircraft only:

Vessel stowage: Other: None

Hazardous materials descriptions and proper shipping names:

Environmentally hazardous substance, solid, n.o.s

Air Transport IATA:

ICAO/IATA Class: 9 ICAO/IATA Subrisk: None UN/ID Number: 3077 Packing Group: III

Special provisions: A97

Cargo Only

Packing Instructions: 400 kg Maximum Qty/Pack: 400 kg

Passenger and Cargo Passenger and Cargo Packing Instructions: 956 Maximum Qty/Pack: 956

Passenger and Cargo Limited Quantity Passenger and Cargo Limited Quantity

Packing Instructions: 30 kg G Maximum Qty/Pack: Y956

Shipping Name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S. *(CONTAINS 1-BROMOADAMANTANE)

Maritime Transport IMDG:

IMDG Class: 9 IMDG Subrisk: None UN Number: 3077 Packing Group: III

EMS Number: F-A, S-F Special provisions: 179 274 335 909

Limited Quantities: 5 kg Marine Pollutant: Yes

Shipping Name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.

Section 15 - REGULATORY INFORMATION

1-bromoadamantane (CAS: 768-90-1) is found on the following regulatory lists;

"Canada - British Columbia Occupational Exposure Limits", "Canada - Prince Edward Island Occupational Exposure Limits", "Canada National Pollutant Release Inventory (NPRI)", "US - California Permissible Exposure Limits for Chemical Contaminants", "US - Michigan Exposure Limits for Air Contaminants", "US - Oregon Permissible Exposure Limits (Z-1)", "US - Tennessee Occupational Exposure Limits For Air Contaminants", "US - Wyoming Toxic and Hazardous Substances Table Z1 Limits for Air Contaminants"

Section 16 - OTHER INFORMATION

ND

Substance CAS Suggested codes 1- bromoadamantane 768-90-1 N; R50/53

Reasonable care has been taken in the preparation of this information, but the author makes no warranty of merchantability or any other warranty, expressed or implied, with respect to this information. The author makes no representations and assumes no liability for any direct, incidental or consequential damages resulting from its use. For additional technical information please call our toxicology department on +800 CHEMCALL.

- Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references.

 A list of reference resources used to assist the committee may be found at:

 www.chemwatch.net/references.
- The (M)SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

This document is copyright. Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from CHEMWATCH. TEL (+61 3) 9572 4700.

Issue Date: Nov-9-2009 Print Date: Apr-7-2011